MX2010001020A - Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas. - Google Patents

Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.

Info

Publication number
MX2010001020A
MX2010001020A MX2010001020A MX2010001020A MX2010001020A MX 2010001020 A MX2010001020 A MX 2010001020A MX 2010001020 A MX2010001020 A MX 2010001020A MX 2010001020 A MX2010001020 A MX 2010001020A MX 2010001020 A MX2010001020 A MX 2010001020A
Authority
MX
Mexico
Prior art keywords
organic compounds
salt
compounds
phosphatidylinositol
solvate
Prior art date
Application number
MX2010001020A
Other languages
English (en)
Inventor
Ian Bruce
Andrew Dunstan
Catherine Howsham
Thomas Anthony Hunt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010001020A publication Critical patent/MX2010001020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención se refiere a un compuesto de la fórmula (ver formula l) o una sal, adecuadamente una sal farmacéuticamente aceptable, o solvato del mismo, en donde los grupos R1, R2, Ar´, A y 8 son definidos en la descripción, a composiciones y uso de los compuestos en el tratamiento de enfermedades mejoradas por la inhibición de fosfatidilinositol 3-cinasa.
MX2010001020A 2007-07-26 2008-07-24 Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas. MX2010001020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07113237 2007-07-26
PCT/EP2008/059748 WO2009013348A2 (en) 2007-07-26 2008-07-24 Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions

Publications (1)

Publication Number Publication Date
MX2010001020A true MX2010001020A (es) 2010-03-01

Family

ID=38942282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001020A MX2010001020A (es) 2007-07-26 2008-07-24 Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.

Country Status (21)

Country Link
EP (1) EP2173722B1 (es)
JP (1) JP5485884B2 (es)
KR (1) KR20100025006A (es)
CN (1) CN101765591B (es)
AR (1) AR067869A1 (es)
AU (1) AU2008278966B2 (es)
BR (1) BRPI0813629A2 (es)
CA (1) CA2694275A1 (es)
CL (1) CL2008002185A1 (es)
CO (1) CO6290670A2 (es)
CR (1) CR11208A (es)
EA (1) EA201000104A1 (es)
EC (1) ECSP109900A (es)
ES (1) ES2394126T3 (es)
MA (1) MA31594B1 (es)
MX (1) MX2010001020A (es)
PE (1) PE20090880A1 (es)
SV (1) SV2010003464A (es)
TN (1) TN2010000038A1 (es)
TW (1) TW200909426A (es)
WO (1) WO2009013348A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
GB0815947D0 (en) * 2008-09-02 2008-10-08 Univ Dundee Compounds
CA2755285C (en) 2009-03-20 2014-02-11 Yunxin Y. Bo Inhibitors of pi3 kinase
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP4967004B2 (ja) * 2009-09-14 2012-07-04 東京エレクトロン株式会社 レジスト塗布現像装置およびレジスト塗布現像方法
ES2908042T3 (es) 2014-01-14 2022-04-27 Takeda Pharmaceuticals Co Heteroarilos y usos de los mismos
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN106458966B (zh) * 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
JP6454727B2 (ja) 2014-04-24 2019-01-16 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピリジン誘導体
EP3134397A1 (en) * 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
MX2020006613A (es) * 2017-12-22 2020-11-13 Ravenna Pharmaceuticals Inc Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa.
SG11202008560VA (en) 2018-03-08 2020-10-29 Incyte Corp AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024782A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
PL203805B1 (pl) * 2000-02-25 2009-11-30 Hoffmann La Roche Zastosowanie cyklicznych związków heteroaromatycznych, lek i cykliczne związki heteroaromatyczne
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US20030208067A1 (en) * 2001-05-30 2003-11-06 Cao Sheldon Xiaodong Inhibitors of protein kinase for the treatment of disease
AUPR688101A0 (en) * 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI330183B (es) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
AU2002950853A0 (en) * 2002-08-19 2002-09-12 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compound and pharmaceutical use thereof
CA2499497A1 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
SI2316831T1 (sl) * 2002-11-21 2013-07-31 Novartis Ag 2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka
ATE527250T1 (de) * 2002-11-21 2011-10-15 Novartis Ag 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs
DK1603570T5 (da) * 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
EP1641535A4 (en) * 2003-06-30 2008-05-14 Merck & Co Inc 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
ES2229928B1 (es) * 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
EP1781654A1 (en) * 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
SE0402735D0 (sv) * 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
CA2601257A1 (en) * 2005-03-10 2006-09-21 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
MX2008012096A (es) * 2006-03-22 2008-12-17 Vertex Pharma Inhibidores de proteina cinasa c-met para el tratamiento de trastornos proliferativos.
GB0608820D0 (en) * 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
GB0610242D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
CA2657200A1 (en) * 2006-07-28 2008-01-31 Novartis Ag 2,4-substituted quinazolines as lipid kinase inhibitors
EP2057158B8 (en) * 2006-08-30 2015-09-30 Cellzome Limited Triazole derivatives as kinase inhibitors
TWI444379B (zh) * 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物

Also Published As

Publication number Publication date
TN2010000038A1 (en) 2011-09-26
CN101765591A (zh) 2010-06-30
AR067869A1 (es) 2009-10-28
CN101765591B (zh) 2013-11-27
EP2173722A2 (en) 2010-04-14
WO2009013348A3 (en) 2009-07-23
MA31594B1 (fr) 2010-08-02
CR11208A (es) 2010-02-12
EA201000104A1 (ru) 2010-08-30
CL2008002185A1 (es) 2009-02-20
AU2008278966A1 (en) 2009-01-29
CA2694275A1 (en) 2009-01-29
ECSP109900A (es) 2010-02-26
CO6290670A2 (es) 2011-06-20
EP2173722B1 (en) 2012-08-29
BRPI0813629A2 (pt) 2018-07-10
WO2009013348A2 (en) 2009-01-29
AU2008278966B2 (en) 2012-02-23
KR20100025006A (ko) 2010-03-08
TW200909426A (en) 2009-03-01
JP2010534634A (ja) 2010-11-11
ES2394126T3 (es) 2013-01-22
SV2010003464A (es) 2010-05-21
PE20090880A1 (es) 2009-08-06
JP5485884B2 (ja) 2014-05-07

Similar Documents

Publication Publication Date Title
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
TN2011000053A1 (en) Organic compounds
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
TW200728307A (en) Novel spirochromanone derivatives
WO2009155121A3 (en) Inhibitors of pi3 kinase
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
MX2007013624A (es) Inhibidores de proteina cinasa.
TW200626158A (en) Naphthaline derivatives
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
MX2012004089A (es) Inhibidores de hsp90.
TW200637817A (en) 5-aminoindole derivatives
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
TW200716547A (en) Piperidin-4-yl-amide derivatives
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal